GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Lavipharm SA (ATH:LAVI) » Definitions » Debt-to-Revenue

Lavipharm (ATH:LAVI) Debt-to-Revenue : 0.59 (As of Jun. 2024)


View and export this data going back to 1995. Start your Free Trial

What is Lavipharm Debt-to-Revenue?

Debt-to-Revenue measures a company's ability to pay off its debt.

Lavipharm's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Jun. 2024 was €8.88 Mil. Lavipharm's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Jun. 2024 was €22.32 Mil. Lavipharm's annualized Revenue for the quarter that ended in Jun. 2024 was €52.62 Mil. Lavipharm's annualized Debt-to-Revenue for the quarter that ended in Jun. 2024 was 0.59.


Lavipharm Debt-to-Revenue Historical Data

The historical data trend for Lavipharm's Debt-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Lavipharm Debt-to-Revenue Chart

Lavipharm Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Debt-to-Revenue
Get a 7-Day Free Trial 1.21 1.04 0.94 0.95 0.64

Lavipharm Semi-Annual Data
Dec17 Dec18 Dec19 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24
Debt-to-Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only 0.85 1.04 0.69 0.65 0.59

Competitive Comparison of Lavipharm's Debt-to-Revenue

For the Drug Manufacturers - Specialty & Generic subindustry, Lavipharm's Debt-to-Revenue, along with its competitors' market caps and Debt-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Lavipharm's Debt-to-Revenue Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Lavipharm's Debt-to-Revenue distribution charts can be found below:

* The bar in red indicates where Lavipharm's Debt-to-Revenue falls into.


;
;

Lavipharm Debt-to-Revenue Calculation

Debt-to-Revenue measures a company's ability to pay off its debt.

Lavipharm's Debt-to-Revenue for the fiscal year that ended in Dec. 2023 is calculated as

Debt-to-Revenue=Total Debt / Revenue
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Revenue
=(8.677 + 23.696) / 50.929
=0.64

Lavipharm's annualized Debt-to-Revenue for the quarter that ended in Jun. 2024 is calculated as

Debt-to-Revenue=Total Debt / Revenue
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Revenue
=(8.884 + 22.321) / 52.618
=0.59

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Debt-to-Revenue, the Revenue of the last fiscal year is used. In calculating the annualized quarterly data, the Revenue data used here is two times the quarterly (Jun. 2024) Revenue data.


Lavipharm Debt-to-Revenue Related Terms

Thank you for viewing the detailed overview of Lavipharm's Debt-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.


Lavipharm Business Description

Traded in Other Exchanges
Address
Agias Marinas Street, PO Box 59, Peania Attica, GRC, 19002
Lavipharm SA develops, manufactures, markets and distributes pharmaceutical, cosmetic and consumer health products in Greece and internationally. The company's product portfolio includes safe and effective therapeutic solutions that meet consumer' needs for health and wellbeing. Its main product categories are Cardiology, Oncology, Urology, Neurology, Psychiatry, General Medicine, Self- Treatment and Dermocosmetic care.

Lavipharm Headlines

No Headlines